Co-Diagnostics, Inc. (Nasdaq: CODX) announced on November 19, 2026, that it has filed Articles of Amendment to its Articles of Incorporation to implement a 1-for-25 reverse stock split. The split will become effective at 12:01 a.m. Eastern Time on Tuesday, November 24, 2026. The company stated the move is intended to enable it to maintain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market and to maintain sufficient authorized shares available for future equity financings.

According to the filing, the reverse stock split will combine every 25 shares of issued and outstanding common stock into one issued and outstanding share. The par value per share will remain unchanged at $0.001. The company will not issue fractional shares; instead, holders who would otherwise receive a fractional share will receive one whole share. All stock options and warrants outstanding immediately prior to the split will be proportionally adjusted, with the number of shares decreasing and the exercise price increasing accordingly.

Immediately following the reverse stock split, the company expects approximately 521,779 shares of common stock to be issued and outstanding. The common shares will continue to trade under the symbol "CODX" and will begin trading on a split-adjusted basis when the market opens on November 24, 2026. The new CUSIP number for the common stock will be 189763 303.

The reverse stock split was approved by the company’s stockholders at a special meeting held on November 13, 2026. The board of directors determined the specific 1-for-25 ratio at that time. The company has appointed VStock Transfer, LLC, as the exchange agent for the transaction.